<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="ipex" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">ipex</book-part-id>
      <title-group>
        <title>IPEX Syndrome</title>
        <alt-title alt-title-type="alt-title">Synonyms: Immunodeficiency, Polyendocrinopathy, and Enteropathy X-Linked Syndrome; X-Linked Autoimmunity-Allergic Dysregulation Syndrome (XLAAD); X-Linked Syndrome of Polyendocrinopathy, Immune Dysfunction, and Diarrhea (XPID)</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Hannibal</surname>
            <given-names>Mark C</given-names>
          </name>
          <degrees>MD, PhD</degrees>
          <aff>Division of Genetics<break/>Department of Pediatrics and Communicable Diseases <break/>University of Michigan Medical School<break/>Ann Arbor, Michigan</aff>
          <email>hannibal@umich.edu</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Torgerson</surname>
            <given-names>Troy</given-names>
          </name>
          <degrees>MD, PhD</degrees>
          <aff>Department of Pediatrics <break/>Divisions of Immunology and Rheumatology<break/>University of Washington<break/>Seattle, Washington</aff>
          <email>ttorgers@u.washington.edu</email>
        </contrib>
      </contrib-group>
      <pub-history>
        <date date-type="created">
          <day>19</day>
          <month>10</month>
          <year>2004</year>
        </date>
        <date date-type="updated">
          <day>27</day>
          <month>1</month>
          <year>2011</year>
        </date>
        <date date-type="revised">
          <day>27</day>
          <month>4</month>
          <year>2006</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="hops" document-type="chapter">Hypophosphatasia</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="vws" document-type="chapter"><italic toggle="yes">IRF6</italic>-Related Disorders</related-object>
      <abstract id="ipex.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p>IPEX (Immune dysregulation, Polyendocrinopathy, Enteropathy, X-linked) syndrome is characterized by systemic autoimmunity, typically beginning in the first year of life. Presentation is most commonly the clinical triad of watery diarrhea, eczematous dermatitis, and endocrinopathy (most commonly insulin-dependent diabetes mellitus). Most children have other autoimmune phenomena including Coombs-positive anemia, autoimmune thrombocytopenia, autoimmune neutropenia, and tubular nephropathy. Without aggressive immunosuppression or bone marrow transplantation, the majority of affected males die within the first one to two years of life from metabolic derangements or sepsis; a few with a milder phenotype have survived into the second or third decade of life.</p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>Diagnosis is based on clinical features and on the identification of a pathogenic variant in <italic toggle="yes">FOXP3</italic>. <italic toggle="yes">FOXP3</italic> is the only gene in which pathogenic variants are known to cause IPEX syndrome. Approximately 25% of males with symptoms suggestive of IPEX syndrome have pathogenic variants identified in <italic toggle="yes">FOXP3</italic>.</p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations</italic>: Immunosuppressive agents (e.g., cyclosporin A, FK506) alone or in combination with steroids; sirolimus (rapamycin) for persons in whom FK506 therapy is toxic or ineffective; granulocyte colony stimulating factor (G-CSF, filgrastim) for autoimmune neutropenia; nutritional support; standard treatment of diabetes mellitus and autoimmune thyroid disease. Bone marrow transplantation (BMT) can resolve clinical symptoms.</p>
          <p><italic toggle="yes">Prevention of primary manifestations</italic>: BMT, if performed early in the course of disease.</p>
          <p><italic toggle="yes">Prevention of secondary complications</italic>: Prophylactic antibiotic therapy for those with autoimmune neutropenia or recurrent infections; aggressive management of dermatitis with topical steroids and anti-inflammatory agents to prevent infection.</p>
          <p><italic toggle="yes">Surveillance</italic>: Periodic evaluation of complete blood count, glucose tolerance, thyroid function, kidney function, and liver function for evidence of autoimmune disease.</p>
          <p><italic toggle="yes">Evaluation of relatives at risk</italic>: If the family-specific pathogenic variant is known, <italic toggle="yes">FOXP3</italic> molecular genetic testing in at-risk males immediately after birth to permit early diagnosis and BMT before significant organ damage occurs; otherwise, monitoring at-risk males for symptoms to enable early diagnosis and treatment.</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p>IPEX syndrome is inherited in an X-linked manner. The risk to sibs of the proband depends on the carrier status of the mother. If the mother of the proband is a carrier, the chance of transmitting the pathogenic variant in each pregnancy is 50%. Males who inherit the pathogenic variant will be affected; females who inherit the pathogenic variant are carriers and will not be affected. Affected males pass the pathogenic variant to all of their daughters and none of their sons. Carrier testing for at-risk relatives and prenatal testing for pregnancies at risk are possible for families in which the pathogenic variant has been identified.</p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="ipex.Diagnosis">
        <title>Diagnosis</title>
        <sec id="ipex.Clinical_Diagnosis">
          <title>Clinical Diagnosis</title>
          <p>The term IPEX is an acronym for <bold>i</bold>mmune dysregulation, <bold>p</bold>olyendocrinopathy, <bold>e</bold>nteropathy, <bold>X</bold>-linked. A clinical triad resulting from widespread autoimmunity suggests a diagnosis of IPEX syndrome:</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Endocrinopathy,</bold> most commonly type 1 diabetes mellitus with onset in the first months or years of life. Autoimmune thyroid disease leading to hypothyroidism or hyperthyroidism has also been observed [<xref ref-type="bibr" rid="ipex.REF.wildin.2002.537">Wildin et al 2002</xref>, <xref ref-type="bibr" rid="ipex.REF.gambineri.2003.430">Gambineri et al 2003</xref>].</p>
            </list-item>
            <list-item>
              <p><bold>Enteropathy</bold> that manifests as chronic watery diarrhea. Onset is typically in the first months of life; villous atrophy with a mononuclear cell infiltrate (activated T cells) in the lamina propria is the most common finding in biopsy.</p>
            </list-item>
            <list-item>
              <p><bold>Dermatitis,</bold> most commonly eczematous. Erythroderma, exfoliative dermatitis, psoriasis-like lesions, and pemphigus nodularis have also been observed [<xref ref-type="bibr" rid="ipex.REF.nieves.2004.466">Nieves et al 2004</xref>, <xref ref-type="bibr" rid="ipex.REF.mcginness.2006.143">McGinness et al 2006</xref>].</p>
            </list-item>
          </list>
        </sec>
        <sec id="ipex.Testing">
          <title>Testing</title>
          <p>No laboratory findings specifically identify affected individuals. Evidence of <bold>immune dysregulation</bold> manifested by the following is suggestive of the syndrome:</p>
          <list list-type="bullet">
            <list-item>
              <p>Elevated serum concentration of immunoglobulin E (IgE) and in some cases, IgA</p>
            </list-item>
            <list-item>
              <p>Eosinophilia</p>
            </list-item>
            <list-item>
              <p>Autoimmune anemia, thrombocytopenia, and/or neutropenia</p>
            </list-item>
            <list-item>
              <p>Autoantibodies to pancreatic islet antigens, thyroid antigens, small bowel mucosa, and other autoantigens</p>
            </list-item>
            <list-item>
              <p>Decreased numbers of FOXP3-expressing T cells in peripheral blood determined by flow cytometry</p>
            </list-item>
          </list>
          <p>
            <bold>Normal findings</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Serum concentration of IgG and IgM</p>
            </list-item>
            <list-item>
              <p>Circulating leukocyte counts</p>
            </list-item>
            <list-item>
              <p>T- and B-cell subsets [<xref ref-type="bibr" rid="ipex.REF.ferguson.2000.390">Ferguson et al 2000</xref>, <xref ref-type="bibr" rid="ipex.REF.wildin.2002.537">Wildin et al 2002</xref>]. Occasionally an expanded population of cells expresses markers of T cell activation and commitment (e.g., HLA-DR, CD45RO).</p>
            </list-item>
            <list-item>
              <p>Neutrophil function</p>
            </list-item>
            <list-item>
              <p>Serum concentration of complement</p>
            </list-item>
            <list-item>
              <p>In vitro proliferative responses of T lymphocytes to common mitogens (e.g., phytohemagglutinin, cross-linking of CD3) or activation with specific antigen (e.g., tetanus, candida). Peripheral blood mononuclear cells from individuals with IPEX syndrome show an excess production of the Th2 cytokines IL-4, IL-5, IL-10, and IL-13 and decreased production of the Th1 cytokine interferon-&#x003b3; [<xref ref-type="bibr" rid="ipex.REF.chatila.2000.r75">Chatila et al 2000</xref>, <xref ref-type="bibr" rid="ipex.REF.nieves.2004.466">Nieves et al 2004</xref>].</p>
            </list-item>
          </list>
          <p>Note: Caution must be exercised when interpreting data regarding the immune responses of individuals with IPEX syndrome as many are on immunosuppressants at the time of diagnosis.</p>
          <sec id="ipex.Molecular_Genetic_Testing">
            <title>Molecular Genetic Testing</title>
            <p><bold>Gene.</bold>
<italic toggle="yes">FOXP3</italic> is the only gene in which pathogenic variants are known to cause IPEX syndrome.</p>
            <p><bold>Evidence for locus heterogeneity.</bold>
<xref ref-type="bibr" rid="ipex.REF.owen.2003.6034">Owen et al [2003]</xref> suggest the possibility of an additional autosomal locus. Among the males who lack <italic toggle="yes">FOXP3</italic> pathogenic variants, approximately half have low <italic toggle="yes">FOXP3</italic> mRNA expression levels and low numbers of FOXP3-expressing cells in peripheral blood [Torgerson, unpublished results], suggesting that defects in other genes or gene products, possibly in the same pathway as FOXP3, may cause a similar phenotype.</p>
            <p>
              <bold>Clinical testing</bold>
            </p>
            <list list-type="bullet">
              <list-item>
                <p><bold>Sequence analysis</bold> of all exons, exon/intron boundaries, and the first polyadenylation site detects pathogenic variants in approximately 25% of males with a clinical phenotype suggestive of IPEX syndrome [Torgerson, unpublished results].</p>
              </list-item>
            </list>
            <table-wrap id="ipex.T.summary_of_molecular_genetic_test" orientation="portrait" position="anchor">
              <label>Table 1. </label>
              <caption>
                <p>Summary of Molecular Genetic Testing Used in IPEX Syndrome</p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th id="hd_h_ipex.T.summary_of_molecular_genetic_test_1_1_1_1" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_ipex.T.summary_of_molecular_genetic_test_1_1_1_1">Gene&#x000a0;<sup>1</sup></th>
                    <th id="hd_h_ipex.T.summary_of_molecular_genetic_test_1_1_1_2" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_ipex.T.summary_of_molecular_genetic_test_1_1_1_2">Test Method</th>
                    <th id="hd_h_ipex.T.summary_of_molecular_genetic_test_1_1_1_3" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_ipex.T.summary_of_molecular_genetic_test_1_1_1_3">Pathogenic Variants Detected&#x000a0;<sup>2</sup></th>
                    <th id="hd_h_ipex.T.summary_of_molecular_genetic_test_1_1_1_4" valign="middle" colspan="2" align="left" scope="colgroup" rowspan="1">Variant Detection Frequency by Test Method&#x000a0;<sup>3</sup></th>
                  </tr>
                  <tr>
                    <th headers="hd_h_ipex.T.summary_of_molecular_genetic_test_1_1_1_4" id="hd_h_ipex.T.summary_of_molecular_genetic_test_1_1_2_1" valign="middle" colspan="1" align="left" scope="colgroup" rowspan="1">Males</th>
                    <th headers="hd_h_ipex.T.summary_of_molecular_genetic_test_1_1_1_4" id="hd_h_ipex.T.summary_of_molecular_genetic_test_1_1_2_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Heterozygous Females</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td headers="hd_h_ipex.T.summary_of_molecular_genetic_test_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                      <italic toggle="yes">FOXP3</italic>
                    </td>
                    <td headers="hd_h_ipex.T.summary_of_molecular_genetic_test_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>4</sup></td>
                    <td headers="hd_h_ipex.T.summary_of_molecular_genetic_test_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Sequence variants</td>
                    <td headers="hd_h_ipex.T.summary_of_molecular_genetic_test_1_1_1_4 hd_h_ipex.T.summary_of_molecular_genetic_test_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">&#x0003e;95%&#x000a0;<sup>5</sup></td>
                    <td headers="hd_h_ipex.T.summary_of_molecular_genetic_test_1_1_1_4 hd_h_ipex.T.summary_of_molecular_genetic_test_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">&#x0003e;95%&#x000a0;<sup>6</sup></td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn>
                  <p>See <related-object source-id="gene" document-id="ipex" object-id="ipex.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein.</p>
                </fn>
                <fn id="ipex.TF.1.1">
                  <label>2. </label>
                  <p>See <xref ref-type="sec" rid="ipex.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants.</p>
                </fn>
                <fn id="ipex.TF.1.2">
                  <label>3. </label>
                  <p>The ability of the test method used to detect a variant that is present in the indicated gene</p>
                </fn>
                <fn id="ipex.TF.1.3">
                  <label>4. </label>
                  <p>Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
                </fn>
                <fn id="ipex.TF.1.4">
                  <label>5. </label>
                  <p>Lack of amplification by PCRs prior to sequence analysis can suggest a putative deletion of one or more exons or the entire X-linked gene in a male; confirmation may require additional testing by deletion/duplication analysis.</p>
                </fn>
                <fn id="ipex.TF.1.5">
                  <label>6. </label>
                  <p>Sequence analysis of genomic DNA cannot detect exon or whole-gene deletions on the X chromosome in carrier females.</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
          </sec>
        </sec>
        <sec id="ipex.Testing_Strategy">
          <title>Testing Strategy</title>
          <p>
            <bold>To confirm/establish the diagnosis in a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Assessment of general immune function including blood cell counts and white blood cell differential</p>
            </list-item>
            <list-item>
              <p>Analysis of T- and B-cell subsets</p>
            </list-item>
            <list-item>
              <p>Measurement of serum concentration of immunoglobulins including IgE</p>
            </list-item>
            <list-item>
              <p>Screening for autoimmune liver and renal disease with measurement of serum concentration of aspartate aminotransferase (AST), alanine aminotransferase (ALT), blood urea nitrogen (BUN), and creatinine; urinalysis</p>
            </list-item>
            <list-item>
              <p>Flow cytometry to evaluate regulatory T cells for expression of both FOXP3 and CD25 (helpful as an initial screen for the disorder)</p>
            </list-item>
            <list-item>
              <p>Sequence analysis of <italic toggle="yes">FOXP3</italic> for definitive diagnosis</p>
            </list-item>
          </list>
          <p><bold>Carrier testing for at-risk relatives</bold> requires prior identification of the pathogenic variants in the family.</p>
          <p>Note: (1) Carriers are heterozygotes for this X-linked disorder but do not exhibit clinical features of IPEX syndrome. (2) Identification of female carriers requires either (a) prior identification of the pathogenic variant in the family or, (b) if an affected male or obligate carrier female is not available for testing, sequence analysis of the at-risk female.</p>
          <p><bold>Prenatal diagnosis and preimplantation genetic diagnosis (PGD)</bold> for at-risk pregnancies require prior identification of the pathogenic variant in the family.</p>
        </sec>
      </sec>
      <sec id="ipex.Clinical_Characteristics">
        <title>Clinical Characteristics</title>
        <sec id="ipex.Clinical_Description">
          <title>Clinical Description</title>
          <p><bold>Males.</bold> IPEX syndrome is generally considered to be a syndrome of neonatal enteropathy [<xref ref-type="bibr" rid="ipex.REF.ruemmele.2004.587">Ruemmele et al 2004</xref>] and neonatal polyendocrinopathy [<xref ref-type="bibr" rid="ipex.REF.dotta.2002.283">Dotta &#x00026; Vendrame 2002</xref>]. The most common presentation of IPEX syndrome is severe watery diarrhea, type 1 insulin-dependent diabetes mellitus, thyroiditis, and dermatitis in males younger than age six months. It is frequently accompanied by other autoimmune phenomena. Males with a somewhat milder disease phenotype can present at older ages but no affected individuals are known to have survived beyond the third decade of life.</p>
          <p>The enteropathy of IPEX syndrome, often the first symptom, is present in virtually all affected individuals. Even in those with milder disease, the diarrhea typically begins in the first six to12 months of life. Watery diarrhea, which may at times also have mucus and blood, leads to malabsorption, failure to thrive, and cachexia, often requiring the use of total parenteral nutrition (TPN). Food allergies are common [<xref ref-type="bibr" rid="ipex.REF.torgerson.2007.1705">Torgerson et al 2007</xref>].</p>
          <p>Endocrinopathy is present in the majority of affected individuals. Type 1 diabetes mellitus, often with onset in the first months of life, is the most common endocrine manifestation. Thyroid disease (most often hypothyroidism) is also common [<xref ref-type="bibr" rid="ipex.REF.wildin.2002.537">Wildin et al 2002</xref>, <xref ref-type="bibr" rid="ipex.REF.gambineri.2003.430">Gambineri et al 2003</xref>].</p>
          <p>The dermatitis is most frequently eczematous, although erythroderma, psoriasiform dermatitis, and pemphigus nodularis have also been described [<xref ref-type="bibr" rid="ipex.REF.nieves.2004.466">Nieves et al 2004</xref>, <xref ref-type="bibr" rid="ipex.REF.mcginness.2006.143">McGinness et al 2006</xref>].</p>
          <p>The outcome of IPEX syndrome is universally poor. Most children die within the first or second year of life from metabolic derangements, severe malabsorption, or sepsis. Although improvements in immunosuppressive regimens and bone marrow transplantation (BMT) have prolonged survival, even those with the mildest disease have survived only into the second or third decades of life [<xref ref-type="bibr" rid="ipex.REF.powell.1982.731">Powell et al 1982</xref>, <xref ref-type="bibr" rid="ipex.REF.kobayashi.2001.874">Kobayashi et al 2001</xref>, <xref ref-type="bibr" rid="ipex.REF.levylahad.2001.577">Levy-Lahad &#x00026; Wildin 2001</xref>, <xref ref-type="bibr" rid="ipex.REF.taddio.2007.1195">Taddio et al 2007</xref>].</p>
          <p>Most affected individuals have other autoimmune phenomena including Coombs-positive anemia, immune thrombocytopenia, autoimmune neutropenia, hepatitis, and tubular nephropathy. Lymphadenopathy, splenomegaly, and alopecia have also been reported <xref ref-type="bibr" rid="ipex.REF.powell.1982.731">Powell et al [1982]</xref>, <xref ref-type="bibr" rid="ipex.REF.ferguson.2000.390">Ferguson et al [2000]</xref>.</p>
          <p>Severe or invasive infections including sepsis, meningitis, pneumonia, and osteomyelitis affect more than 50% of individuals with IPEX syndrome [<xref ref-type="bibr" rid="ipex.REF.gambineri.2008.1105">Gambineri et al 2008</xref>; Torgerson, unpublished results]. The most common pathogens identified were <italic toggle="yes">Staphylococcus</italic>, <italic toggle="yes">Enterococcus,</italic> cytomegalovirus, and <italic toggle="yes">Candida</italic>. Some infections may be secondary to immunosuppressive therapy; however, many occur prior to the initiation of treatment. It is unclear, however, whether individuals with IPEX syndrome truly have an increased susceptibility to infectious pathogens or whether their infections are related to the poor barrier function of the gut and skin.</p>
          <p><bold>Female carriers</bold> of <italic toggle="yes">FOXP3</italic> pathogenic variants are generally healthy. However,</p>
          <list list-type="bullet">
            <list-item>
              <p>One female carrier had an expression level of <italic toggle="yes">FOXP3</italic> mRNA intermediate between the very low level observed in her affected son and the normal level in a control [<xref ref-type="bibr" rid="ipex.REF.bennett.2001.435">Bennett et al 2001</xref>].</p>
            </list-item>
            <list-item>
              <p>One carrier female has type I diabetes mellitus.</p>
            </list-item>
            <list-item>
              <p>X-chromosome inactivation studies performed on one carrier female demonstrated that normal and mutated <italic toggle="yes">FOXP3</italic> alleles are equally expressed in peripheral blood mononuclear cells [<xref ref-type="bibr" rid="ipex.REF.tommasini.2002.127">Tommasini et al 2002</xref>]. However, subsequent studies of the FOXP3+ regulatory T cell population demonstrated a selective advantage for cells utilizing the normal X chromosome, resulting in complete skewing of X chromosome usage in this cell subset [<xref ref-type="bibr" rid="ipex.REF.di_nunzio.2009.4138">Di Nunzio et al 2009</xref>].</p>
            </list-item>
          </list>
        </sec>
        <sec id="ipex.GenotypePhenotype_Correlations">
          <title>Genotype-Phenotype Correlations</title>
          <p>As a rule, males with pathogenic variants that abrogate expression of functional FOXP3 protein (nonsense, frameshift, or splicing variants) have severe, early-onset IPEX syndrome.</p>
          <p>Mutation of the first polyadenylation signal of the gene with an otherwise normal gene sequence leads to low expression levels of normal <italic toggle="yes">FOXP3</italic> mRNA and generally results in severe, early-onset disease as well [<xref ref-type="bibr" rid="ipex.REF.bennett.2001.435">Bennett et al 2001</xref>]. In one of the three kindreds with this type of pathogenic variant, two affected males had mild, late-onset disease and lived into the second and third decades of life, suggesting that other modifying factors that affect mRNA stability may be the cause of the observed variability [<xref ref-type="bibr" rid="ipex.REF.powell.1982.731">Powell et al 1982</xref>].</p>
          <p>A number of affected individuals have missense (single-nucleotide) variants that result in expression of mutated proteins, some of which appear to be functionally hypomorphic and are associated with a milder clinical phenotype [<xref ref-type="bibr" rid="ipex.REF.de_benedetti.2006.653">De Benedetti et al 2006</xref>, <xref ref-type="bibr" rid="ipex.REF.lopes.2006.3133">Lopes et al 2006</xref>, <xref ref-type="bibr" rid="ipex.REF.gavin.2006.6659">Gavin et al 2006</xref>, <xref ref-type="bibr" rid="ipex.REF.d_hennezel.2009.1710">d&#x02019;Hennezel et al 2009</xref>, <xref ref-type="bibr" rid="ipex.REF.mcmurchy.2010.1242">McMurchy et al 2010</xref>].</p>
        </sec>
        <sec id="ipex.Prevalence">
          <title>Prevalence</title>
          <p>IPEX syndrome is rare: fewer than 150 affected individuals have been identified worldwide. No accurate estimates of prevalence have been published. It is, however, likely to be underreported judging by the prevalence of other syndromes caused by pathogenic variants in similarly sized genes located nearby on the X chromosome (e.g., <related-object link-type="booklink" source-id="gene" document-id="was" document-type="chapter">Wiskott-Aldrich syndrome</related-object>).</p>
        </sec>
      </sec>
      <sec id="ipex.Genetically_Related_Allelic_Disorde">
        <title>Genetically Related (Allelic) Disorders</title>
        <p>No other phenotypes are known to be associated with pathogenic variants in <italic toggle="yes">FOXP3</italic>.</p>
        <p>No contiguous gene deletion syndromes that include deletion of <italic toggle="yes">FOXP3</italic> have been reported.</p>
      </sec>
      <sec id="ipex.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <p>
          <bold>Other syndromes with neonatal diabetes mellitus</bold>
        </p>
        <list list-type="bullet">
          <list-item>
            <p><related-object link-type="booklink" source-id="gene" document-id="dmtn" document-type="chapter">Transient neonatal diabetes mellitus</related-object> caused by an imprinting disorder involving chromosome region 6q24</p>
          </list-item>
          <list-item>
            <p>Pancreatic hypoplasia or agenesis caused by recessive insulin promoter factor-1 pathogenic variants (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.omim.org/entry/260370">260370</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.omim.org/entry/600733">600733</ext-link>)</p>
          </list-item>
          <list-item>
            <p>Dominant pancreatic hypoplasia associated with congenital heart disease (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.omim.org/entry/600001">600001</ext-link>)</p>
          </list-item>
          <list-item>
            <p>A presumed recessive disorder or imprinting defect causing an islet cell developmental defect (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.omim.org/entry/600089">600089</ext-link>)</p>
          </list-item>
        </list>
        <p>
          <bold>Other syndromes of polyendocrinopathy</bold>
        </p>
        <list list-type="bullet">
          <list-item>
            <p>Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) (APS I) (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.omim.org/entry/240300">240300</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.omim.org/entry/607358">607358</ext-link>) (autoimmune polyglandular failure)</p>
          </list-item>
          <list-item>
            <p>Schmidt syndrome (APS II/III) (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.omim.org/entry/269200">269200</ext-link>)</p>
          </list-item>
          <list-item>
            <p><related-object link-type="booklink" source-id="gene" document-id="alps" document-type="chapter">Autoimmune lymphoproliferative syndrome</related-object> (ALPS) characterized by hemolytic anemia, thrombocytopenia, and splenomegaly; type 1 diabetes mellitus; and thyroid disease</p>
          </list-item>
        </list>
        <p>
          <bold>Other syndromes with immunodeficiency</bold>
        </p>
        <list list-type="bullet">
          <list-item>
            <p>CD25 (IL2RA) deficiency (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.omim.org/entry/606367">606367</ext-link>), identified in three individuals with an IPEX syndrome-like clinical phenotype [<xref ref-type="bibr" rid="ipex.REF.roifman.2000.6">Roifman 2000</xref>, <xref ref-type="bibr" rid="ipex.REF.caudy.2007.482">Caudy et al 2007</xref>]. In addition to autoimmunity, however, these individuals also had features of severe cellular immunodeficiency with susceptibility to severe cytomegalovirus infections. Unlike IPEX syndrome, CD25 deficiency has normal IgE. CD25 deficiency is inherited in an autosomal recessive manner.</p>
          </list-item>
          <list-item>
            <p>STAT5B deficiency (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.omim.org/entry/245590">245590</ext-link>), identified in ten individuals worldwide with a syndrome of autoimmunity and immune deficiency characterized by low but not absent T and NK cell numbers as well as decreased FOXP3 protein expression [<xref ref-type="bibr" rid="ipex.REF.cohen.2006.2770">Cohen et al 2006</xref>]. In addition to the immunologic problems, affected individuals also have a form of dwarfism related to the fact that growth hormone mediates its effects through STAT5 [<xref ref-type="bibr" rid="ipex.REF.kofoed.2003.1139">Kofoed et al 2003</xref>]. STAT5B deficiency is inherited in an autosomal recessive manner.</p>
          </list-item>
          <list-item>
            <p><related-object link-type="booklink" source-id="gene" document-id="was" document-type="chapter">Wiskott-Aldrich syndrome</related-object>, characterized by thrombocytopenia, eczema, and a combined immune deficiency. Inheritance is X-linked.</p>
          </list-item>
          <list-item>
            <p>Omenn syndrome, also known as familial reticuloendotheliosis with eosinophilia or severe combined immunodeficiency (SCID) with hypereosinophilia, caused by pathogenic variants in <italic toggle="yes">DCLRE1C</italic>, <italic toggle="yes">RAG1</italic>, and <italic toggle="yes">RAG2</italic> (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.omim.org/entry/179615">179615</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.omim.org/entry/179616">179616</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.omim.org/entry/603554">603554</ext-link>)</p>
          </list-item>
        </list>
        <p><bold>Other syndromes with protracted diarrhea in infancy</bold> [<xref ref-type="bibr" rid="ipex.REF.sherman.2004.16">Sherman et al 2004</xref>]</p>
        <list list-type="bullet">
          <list-item>
            <p>Microvillus inclusion disease</p>
          </list-item>
          <list-item>
            <p>Tufting enteropathy</p>
          </list-item>
          <list-item>
            <p>Autoimmune enteropathy</p>
          </list-item>
          <list-item>
            <p>IL-10 receptor deficiency (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.omim.org/entry/613148">613148</ext-link>), reported in two consanguineous families; results in a severe, early-onset, fistulating enterocolitis [<xref ref-type="bibr" rid="ipex.REF.glocker.2009.2033">Glocker et al 2009</xref>]. Inheritance is autosomal recessive.</p>
          </list-item>
        </list>
      </sec>
      <sec id="ipex.Management">
        <title>Management</title>
        <sec id="ipex.Evaluations_Following_Initial_Diagn">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>To establish the extent of disease in an individual diagnosed with IPEX syndrome, the following evaluations are recommended:</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Endocrine.</bold> Glucose tolerance test, thyroid function tests, and autoantibodies to pancreatic islet antigens and thyroid antigens</p>
            </list-item>
            <list-item>
              <p><bold>Hematologic.</bold> Complete blood count and differential, Coombs test</p>
            </list-item>
            <list-item>
              <p><bold>Immunologic.</bold> Serum IgG, IgM, IgA, and IgE concentrations; regulatory T cell numbers</p>
            </list-item>
            <list-item>
              <p><bold>Hepatic.</bold> Serum AST, ALT, GGT, and total bilirubin</p>
            </list-item>
            <list-item>
              <p><bold>Renal.</bold> Serum concentration of BUN and creatinine; urinalysis</p>
            </list-item>
            <list-item>
              <p><bold>Nutrition assessment.</bold> Serum electrolyte levels including calcium, magnesium, and zinc; serum albumin and pre-albumin</p>
            </list-item>
          </list>
        </sec>
        <sec id="ipex.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <p>Monitor fluid intake to assure adequate intravascular volume.</p>
          <p>Use of nutritional support, including TPN or elemental or low-carbohydrate-containing formula if necessary, can be beneficial [<xref ref-type="bibr" rid="ipex.REF.sherman.2004.16">Sherman et al 2004</xref>].</p>
          <p>Follow the standard treatment protocols for diabetes mellitus and autoimmune thyroid disease.</p>
          <p>The most effective treatment for the enteropathy of IPEX syndrome is T cell-directed immune suppression (i.e., cyclosporin A and FK506) either alone or in combination with steroids [<xref ref-type="bibr" rid="ipex.REF.di_rocco.1996.f144">Di Rocco &#x00026; Marta 1996</xref>]. Toxicity, tachyphylaxis, and increased susceptibility to infection related to chronic use of these agents reduce their potential for long-term amelioration of symptoms in most individuals.</p>
          <p>Sirolimus (rapamycin) has been successfully used in patients for whom FK506 was either ineffective or toxic [<xref ref-type="bibr" rid="ipex.REF.bindl.2005.256">Bindl et al 2005</xref>, <xref ref-type="bibr" rid="ipex.REF.yong.2008.581">Yong et al 2008</xref>]. The ability of sirolimus to suppress effector T cell function while allowing Treg cells to continue to develop and function offers some theoretic advantages for its use [<xref ref-type="bibr" rid="ipex.REF.strauss.2007.320">Strauss et al 2007</xref>].</p>
          <p>In persons with autoimmune neutropenia, granulocyte colony stimulating factor (G-CSF, filgrastim) may be beneficial.</p>
          <p>In one person who developed pemphigus nodularis, use of rituximab improved pemphigus and other IPEX syndrome-associated symptoms [<xref ref-type="bibr" rid="ipex.REF.mcginness.2006.143">McGinness et al 2006</xref>]. It has also been effective in controlling autoimmune hemolytic anemia, immune thrombocytopenic purpura, and autoimmune neutropenia in persons with IPEX syndrome [Torgerson, unpublished results].</p>
          <p>In persons with severe disease in whom other therapies have failed and symptoms remain severe, cytotoxic drugs or biologic agents that target T cells may be beneficial, as demonstrated by complete remission of symptoms during a bone marrow transplantation conditioning regimen of anti-thymocyte globulin, busulfan, and cyclophosphamide [<xref ref-type="bibr" rid="ipex.REF.baud.2001.1758">Baud et al 2001</xref>].</p>
          <p>Bone marrow transplantation (BMT) offers the only potential cure for IPEX syndrome. Early attempts at BMT using myeloablative conditioning regimens met with only limited success because of transplant-related mortality and other complications related to the underlying disease [<xref ref-type="bibr" rid="ipex.REF.baud.2001.1758">Baud et al 2001</xref>]. Recent approaches using non-myeloablative conditioning regimens have markedly improved outcomes and survival [<xref ref-type="bibr" rid="ipex.REF.burroughs.2007.633">Burroughs et al 2007</xref>, <xref ref-type="bibr" rid="ipex.REF.lucas.2007.55">Lucas et al 2007</xref>, <xref ref-type="bibr" rid="ipex.REF.rao.2007.383">Rao et al 2007</xref>]. While generally less toxic, these reduced-intensity conditioning regimens still appear to generate long-term, stable engraftment of a regulatory T cell population [<xref ref-type="bibr" rid="ipex.REF.burroughs.2010.1000">Burroughs et al 2010</xref>] and, if performed early, can prevent the development of irreversible diabetes mellitus or thyroiditis.</p>
        </sec>
        <sec id="ipex.Prevention_of_Primary_Manifestation">
          <title>Prevention of Primary Manifestations</title>
          <p>BMT is currently the only cure for IPEX syndrome; the degree of symptomatic remission may depend on use of BMT prior to irreversible damage to target organs such as pancreatic islet cells and thyroid.</p>
        </sec>
        <sec id="ipex.Prevention_of_Secondary_Complicatio">
          <title>Prevention of Secondary Complications</title>
          <p>Patients with autoimmune neutropenia or recurrent infections resulting from severe eczema may benefit from prophylactic antibiotic therapy to decrease the risk of severe infectious complications.</p>
          <p>Aggressive management of dermatitis with topical steroids and anti-inflammatory agents can help to prevent infections from pathogens that enter as a result of the poor barrier function of the skin.</p>
        </sec>
        <sec id="ipex.Surveillance">
          <title>Surveillance</title>
          <p>Appropriate surveillance includes periodic evaluation of complete blood count, thyroid function, glucose tolerance, kidney function (measurement of serum concentration of BUN, creatinine), and liver function (measurement of serum concentration of AST, ALT) for evidence of autoimmune disease.</p>
        </sec>
        <sec id="ipex.AgentsCircumstances_to_Avoid">
          <title>Agents/Circumstances to Avoid</title>
          <p>Immune activation, for example by immunizations or severe infections, has been reported to cause worsening or exacerbation of disease symptoms [<xref ref-type="bibr" rid="ipex.REF.powell.1982.731">Powell et al 1982</xref>]. This does not indicate an absolute contraindication for vaccination in IPEX syndrome but does suggest that there may be benefit to giving vaccines individually instead of combining several vaccines on a single day.</p>
        </sec>
        <sec id="ipex.Evaluation_of_Relatives_at_Risk">
          <title>Evaluation of Relatives at Risk</title>
          <p>Molecular genetic testing of at-risk males in a family with a known pathogenic variant either prenatally or immediately after birth enables early diagnosis and BMT in affected males before significant organ damage occurs.</p>
          <p>If the pathogenic variant is not known, monitoring at-risk males for early-onset diarrhea, diabetes mellitus, thyroid dysfunction, and autoimmune hematologic manifestations can allow early identification of affected males.</p>
          <p>See <xref ref-type="sec" rid="ipex.Related_Genetic_Counseling_Issues">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="ipex.Therapies_Under_Investigation">
          <title>Therapies Under Investigation</title>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov/">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p>
        </sec>
        <sec id="ipex.Other">
          <title>Other</title>
          <p>There is no evidence that initiation of immunosuppressive therapy prior to the onset of symptoms prevents the primary manifestations of IPEX syndrome. Bone marrow transplantation prior to the onset of symptoms can, however. prevent disease.</p>
        </sec>
      </sec>
      <sec id="ipex.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="ipex.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p>IPEX syndrome is inherited in an X-linked manner.</p>
        </sec>
        <sec id="ipex.Risk_to_Family_Members">
          <title>Risk to Family Members</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The father of an affected male will not have the disease nor will he be a carrier of the pathogenic variant.</p>
            </list-item>
            <list-item>
              <p>In a family with more than one affected individual, the mother of an affected male is an obligate carrier.</p>
            </list-item>
            <list-item>
              <p>The percentage of affected males who have no family history of IPEX syndrome is not known. If an affected male represents a simplex case, the following possibilities regarding his mother's carrier status and carrier risks of extended family members need to be considered:</p>
              <list list-type="bullet">
                <list-item>
                  <p>The mother is not a carrier and the affected male has a <italic toggle="yes">de novo</italic> pathogenic variant.</p>
                </list-item>
                <list-item>
                  <p>The mother is a carrier of a pathogenic variant.</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>Female carriers of IPEX syndrome are asymptomatic.</p>
            </list-item>
          </list>
          <p>
            <bold>Sibs of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The risk to the sibs depends on the carrier status of the mother.</p>
            </list-item>
            <list-item>
              <p>If the mother of the proband has a pathogenic variant, the chance of transmitting it in each pregnancy is 50%. Males who inherit the variant will be affected; females who inherit the variant are carriers and will not be affected.</p>
            </list-item>
            <list-item>
              <p>If the proband presents a simplex case and if his mother's carrier status is unknown, her risk of being a carrier is unknown.</p>
            </list-item>
            <list-item>
              <p>Germline mosaicism has not been observed.</p>
            </list-item>
          </list>
          <p><bold>Offspring of a proband.</bold> Males pass the pathogenic variant to all of their daughters and none of their sons.</p>
          <p><bold>Other family members.</bold> The proband's maternal aunts and their offspring may be at risk of being carriers or of being affected (depending on their gender, family relationship, and the carrier status of the proband's mother).</p>
        </sec>
        <sec id="ipex.Carrier_Detection">
          <title>Carrier Detection</title>
          <p>Carrier testing of at-risk female relatives is possible if the pathogenic variant in the family has been identified.</p>
          <p>X-chromosome inactivation is skewed only in regulatory T cells [<xref ref-type="bibr" rid="ipex.REF.di_nunzio.2009.4138">Di Nunzio et al 2009</xref>] and is random in all other lymphocyte populations [<xref ref-type="bibr" rid="ipex.REF.tommasini.2002.127">Tommasini et al 2002</xref>]; therefore, X-chromosome inactivation studies are of limited use in carrier detection.</p>
        </sec>
        <sec id="ipex.Related_Genetic_Counseling_Issues">
          <title>Related Genetic Counseling Issues</title>
          <p>See Management, <xref ref-type="sec" rid="ipex.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</xref> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk, clarification of carrier status, and discussion of the availability of prenatal testing is before pregnancy.</p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected, are carriers, or are at risk of being carriers.</p>
            </list-item>
          </list>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.</p>
        </sec>
        <sec id="ipex.Prenatal_Testing">
          <title>Prenatal Testing</title>
          <p>Once the <italic toggle="yes">FOXP3</italic> pathogenic variant has been identified in an affected family member, prenatal testing for a pregnancy at risk for IPEX syndrome is possible.</p>
        </sec>
      </sec>
      <sec id="ipex.Resources">
        <title>Resources</title>
      </sec>
      <sec id="ipex.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <p><bold>Gene structure.</bold> 11 translated exons. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="ipex" object-id="ipex.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
        <p><bold>Pathogenic variants.</bold> The majority of pathogenic variants in <italic toggle="yes">FOXP3</italic> are either frameshift variants that predict a foreshortened protein product or missense variants within the C-terminal forkhead DNA-binding domain. Some pathogenic variants also affect the leucine zipper and a transrepression domain located within the N-terminal proline-rich region of the protein, demonstrating the essential role for these domains in FOXP3 function [<xref ref-type="bibr" rid="ipex.REF.chatila.2000.r75">Chatila et al 2000</xref>, <xref ref-type="bibr" rid="ipex.REF.lopes.2006.3133">Lopes et al 2006</xref>].</p>
        <p><bold>Normal gene product.</bold>
<italic toggle="yes">FOXP3</italic> encodes forkhead box protein P3 (FOXP3), a forkhead DNA-binding protein that is expressed primarily in CD4+CD25+ regulatory T cells. The protein consists of 431 amino acids and has important functional domains including:</p>
        <list list-type="bullet">
          <list-item>
            <p>An N-terminal proline-rich domain that contains sequences essential for the gene suppressive function of FOXP3 and for interaction with other transcription factors including ROR&#x003b1; and ROR&#x003b3;t [<xref ref-type="bibr" rid="ipex.REF.du.2008.4785">Du et al 2008</xref>, <xref ref-type="bibr" rid="ipex.REF.zhou.2008.236">Zhou et al 2008</xref>],</p>
          </list-item>
          <list-item>
            <p>A C2H2 zinc finger and leucine zipper (both conserved structural motifs involved in protein-protein interactions) in the central portion</p>
          </list-item>
          <list-item>
            <p>A forkhead DNA-binding domain at the C terminus from which it derives its name (forkhead box) [<xref ref-type="bibr" rid="ipex.REF.ochs.2005.156">Ochs et al 2005</xref>, <xref ref-type="bibr" rid="ipex.REF.lopes.2006.3133">Lopes et al 2006</xref>]. A putative nuclear localization signal is located at the C-terminal portion of the forkhead domain [<xref ref-type="bibr" rid="ipex.REF.lopes.2006.3133">Lopes et al 2006</xref>].</p>
          </list-item>
        </list>
        <p>Proteins bearing forkhead DNA-binding motifs comprise a large family of related molecules that play diverse roles in enhancing or suppressing transcription from specific binding sites. Several members of this protein family are involved in patterning and development [<xref ref-type="bibr" rid="ipex.REF.gajiwala.2000.110">Gajiwala &#x00026; Burley 2000</xref>]. FOXP3 is expressed primarily in lymphoid tissues (thymus, spleen, and lymph nodes), particularly in CD4+ CD25+ regulatory T lymphocytes. In mice, it is required for the development and suppressive function of this important regulatory T cell population [<xref ref-type="bibr" rid="ipex.REF.fontenot.2003.330">Fontenot et al 2003</xref>, <xref ref-type="bibr" rid="ipex.REF.hori.2003.1057">Hori et al 2003</xref>, <xref ref-type="bibr" rid="ipex.REF.khattri.2003.337">Khattri et al 2003</xref>, <xref ref-type="bibr" rid="ipex.REF.sakaguchi.2003.1310">Sakaguchi 2003</xref>]. In humans, it is not expressed at baseline in CD4+CD25- or CD8+ T cells but is expressed upon T cell activation [<xref ref-type="bibr" rid="ipex.REF.gavin.2006.6659">Gavin et al 2006</xref>, <xref ref-type="bibr" rid="ipex.REF.allan.2007.345">Allan et al 2007</xref>]. The significance of this inducible expression in effector T cells is unknown.</p>
        <p><bold>Abnormal gene product.</bold> The FOXP3 protein is absent in most individuals with IPEX syndrome; some individuals with <italic toggle="yes">FOXP3</italic> single-nucleotide variants express a protein that appears to have decreased function, thereby leading to a milder form of the disease [<xref ref-type="bibr" rid="ipex.REF.de_benedetti.2006.653">De Benedetti et al 2006</xref>, <xref ref-type="bibr" rid="ipex.REF.gambineri.2008.1105">Gambineri et al 2008</xref>].</p>
      </sec>
      <sec id="ipex.References">
        <title>References</title>
        <sec id="ipex.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="ipex.Literature_Cited.reflist0">
            <ref id="ipex.REF.allan.2007.345">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Allan</surname>
                    <given-names>SE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Crome</surname>
                    <given-names>SQ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Crellin</surname>
                    <given-names>NK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Passerini</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Steiner</surname>
                    <given-names>TS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bacchetta</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roncarolo</surname>
                    <given-names>MG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Levings</surname>
                    <given-names>MK</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production.</article-title>
                <source>Int Immunol</source>
                <volume>19</volume>
                <fpage>345</fpage>
                <lpage>54</lpage>
                <pub-id pub-id-type="pmid">17329235</pub-id>
              </element-citation>
            </ref>
            <ref id="ipex.REF.baud.2001.1758">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Baud</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goulet</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Canioni</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Le Deist</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Radford</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rieu</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dupuis-Girod</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cerf-Bensussan</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cavazzana-Calvo</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brousse</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fischer</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Casanova</surname>
                    <given-names>JL</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Treatment of the immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) by allogeneic bone marrow transplantation.</article-title>
                <source>N Engl J Med</source>
                <volume>344</volume>
                <fpage>1758</fpage>
                <lpage>62</lpage>
                <pub-id pub-id-type="pmid">11396442</pub-id>
              </element-citation>
            </ref>
            <ref id="ipex.REF.bennett.2001.435">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bennett</surname>
                    <given-names>CL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brunkow</surname>
                    <given-names>ME</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ramsdell</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>O'Briant</surname>
                    <given-names>KC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhu</surname>
                    <given-names>Q</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fuleihan</surname>
                    <given-names>RL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shigeoka</surname>
                    <given-names>AO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ochs</surname>
                    <given-names>HD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chance</surname>
                    <given-names>PF</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>A rare polyadenylation signal mutation of the FOXP3 gene (AAUAAA--&#x0003e;AAUGAA) leads to the IPEX syndrome.</article-title>
                <source>Immunogenetics</source>
                <volume>53</volume>
                <fpage>435</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">11685453</pub-id>
              </element-citation>
            </ref>
            <ref id="ipex.REF.bindl.2005.256">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bindl</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Torgerson</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Perroni</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Youssef</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ochs</surname>
                    <given-names>HD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goulet</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ruemmele</surname>
                    <given-names>FM</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Successful use of the new immune-suppressor sirolimus in IPEX (immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome).</article-title>
                <source>J Pediatr</source>
                <volume>147</volume>
                <fpage>256</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">16126062</pub-id>
              </element-citation>
            </ref>
            <ref id="ipex.REF.burroughs.2007.633">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Burroughs</surname>
                    <given-names>LM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Storb</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leisenring</surname>
                    <given-names>WM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pulsipher</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Loken</surname>
                    <given-names>MR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Torgerson</surname>
                    <given-names>TR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ochs</surname>
                    <given-names>HD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Woolfrey</surname>
                    <given-names>AE</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Intensive postgrafting immune suppression combined with nonmyeloablative conditioning for transplantation of HLA-identical hematopoietic cell grafts: results of a pilot study for treatment of primary immunodeficiency disorders.</article-title>
                <source>Bone Marrow Transplant</source>
                <volume>40</volume>
                <fpage>633</fpage>
                <lpage>42</lpage>
                <pub-id pub-id-type="pmid">17660844</pub-id>
              </element-citation>
            </ref>
            <ref id="ipex.REF.burroughs.2010.1000">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Burroughs</surname>
                    <given-names>LM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Torgerson</surname>
                    <given-names>TR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Storb</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carpenter</surname>
                    <given-names>PA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rawlings</surname>
                    <given-names>DJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sanders</surname>
                    <given-names>MD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scharenberg</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Skoda-Smith</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Englund</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ochs</surname>
                    <given-names>HD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Woolfrey</surname>
                    <given-names>AE</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Stable hematopoietic cell engraftment after low-intensity nonmyeloablative conditioning in patients with immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome.</article-title>
                <source>J Allergy Clin Immunol</source>
                <volume>126</volume>
                <fpage>1000</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">20643476</pub-id>
              </element-citation>
            </ref>
            <ref id="ipex.REF.caudy.2007.482">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Caudy</surname>
                    <given-names>AA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reddy</surname>
                    <given-names>ST</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chatila</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Atkinson</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Verbsky</surname>
                    <given-names>JW</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>CD25 deficiency causes an immune dysregulation, polyendocrinopathy, enteropathy, X-linked-like syndrome, and defective IL-10 expression from CD4 lymphocytes.</article-title>
                <source>J Allergy Clin Immunol</source>
                <volume>119</volume>
                <fpage>482</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">17196245</pub-id>
              </element-citation>
            </ref>
            <ref id="ipex.REF.chatila.2000.r75">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Chatila</surname>
                    <given-names>TA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blaeser</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ho</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lederman</surname>
                    <given-names>HM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Voulgaropoulos</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Helms</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bowcock</surname>
                    <given-names>AM</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Jm2, encoding a fork head-related protein, is mutated in x-linked autoimmunity-allergic dysregulation syndrome.</article-title>
                <source>J Clin Invest</source>
                <volume>106</volume>
                <fpage>R75</fpage>
                <lpage>81</lpage>
                <pub-id pub-id-type="pmid">11120765</pub-id>
              </element-citation>
            </ref>
            <ref id="ipex.REF.cohen.2006.2770">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Cohen</surname>
                    <given-names>AC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nadeau</surname>
                    <given-names>KC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tu</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hwa</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dionis</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bezrodnik</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Teper</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gaillard</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heinrich</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Krensky</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rosenfeld</surname>
                    <given-names>RG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lewis</surname>
                    <given-names>DB</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Cutting edge: Decreased accumulation and regulatory function of CD4+CD25(high) T cells in human STAT5b deficiency.</article-title>
                <source>J Immunol</source>
                <volume>177</volume>
                <fpage>2770</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">16920911</pub-id>
              </element-citation>
            </ref>
            <ref id="ipex.REF.de_benedetti.2006.653">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>De Benedetti</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Insalaco</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Diamanti</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cortis</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Muratori</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lamioni</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carsetti</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cusano</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Vito</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Perroni</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gambarara</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Castro</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bottazzo</surname>
                    <given-names>GF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ugazio</surname>
                    <given-names>AG</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Mechanistic associations of a mild phenotype of immunodysregulation, polyendocrinopathy, enteropathy, x-linked syndrome.</article-title>
                <source>Clin Gastroenterol Hepatol</source>
                <volume>4</volume>
                <fpage>653</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">16630773</pub-id>
              </element-citation>
            </ref>
            <ref id="ipex.REF.d_hennezel.2009.1710">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>D&#x02019;Hennezel</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ben-Shoshan</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ochs</surname>
                    <given-names>HD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Torgerson</surname>
                    <given-names>TR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Russell</surname>
                    <given-names>LJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lejtenyi</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Noya</surname>
                    <given-names>FJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jabado</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mazer</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Piccirillo</surname>
                    <given-names>CA</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>FOXP3 forkhead domain mutation and regulatory T cells in the IPEX syndrome.</article-title>
                <source>N Engl J Med.</source>
                <volume>361</volume>
                <fpage>1710</fpage>
                <lpage>3</lpage>
                <pub-id pub-id-type="pmid">19846862</pub-id>
              </element-citation>
            </ref>
            <ref id="ipex.REF.di_nunzio.2009.4138">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Di Nunzio</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cecconi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Passerini</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McMurchy</surname>
                    <given-names>AN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baron</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Turbachova</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vignola</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Valencic</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tommasini</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Junker</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cazzola</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Olek</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Levings</surname>
                    <given-names>MK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Perroni</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roncarolo</surname>
                    <given-names>MG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bacchetta</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Wild-type <italic toggle="yes">FOXP3</italic> is selectively active in CD4<sup>+</sup>CD25<sup>hi</sup> regulatory T cells of healthy female carriers of different <italic toggle="yes">FOXP3</italic> mutations.</article-title>
                <source>Blood</source>
                <volume>114</volume>
                <fpage>4138</fpage>
                <lpage>41</lpage>
                <pub-id pub-id-type="pmid">19738030</pub-id>
              </element-citation>
            </ref>
            <ref id="ipex.REF.di_rocco.1996.f144">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Di Rocco</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marta</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <year>1996</year>
                <article-title>X linked immune dysregulation, neonatal insulin dependent diabetes, and intractable diarrhoea.</article-title>
                <source>Arch Dis Child Fetal Neonatal Ed.</source>
                <volume>75</volume>
                <fpage>F144</fpage>
                <pub-id pub-id-type="pmid">8949705</pub-id>
              </element-citation>
            </ref>
            <ref id="ipex.REF.dotta.2002.283">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Dotta</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vendrame</surname>
                    <given-names>F</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Neonatal syndromes of polyendocrinopathy.</article-title>
                <source>Endocrinol Metab Clin North Am</source>
                <volume>31</volume>
                <fpage>283</fpage>
                <lpage>93</lpage>
                <pub-id pub-id-type="pmid">12092451</pub-id>
              </element-citation>
            </ref>
            <ref id="ipex.REF.du.2008.4785">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Du</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Huang</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhou</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ziegler</surname>
                    <given-names>SF</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Isoform-specific inhibition of ROR alpha-mediated transcriptional activation by human FOXP3.</article-title>
                <source>J Immunol</source>
                <volume>180</volume>
                <fpage>4785</fpage>
                <lpage>92</lpage>
                <pub-id pub-id-type="pmid">18354202</pub-id>
              </element-citation>
            </ref>
            <ref id="ipex.REF.ferguson.2000.390">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ferguson</surname>
                    <given-names>PJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blanton</surname>
                    <given-names>SH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Saulsbury</surname>
                    <given-names>FT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McDuffie</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lemahieu</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gastier</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Francke</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Borowitz</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sutphen</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kelly</surname>
                    <given-names>TE</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Manifestations and linkage analysis in X-linked autoimmunity-immunodeficiency syndrome.</article-title>
                <source>Am J Med Genet</source>
                <volume>90</volume>
                <fpage>390</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">10706361</pub-id>
              </element-citation>
            </ref>
            <ref id="ipex.REF.fontenot.2003.330">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Fontenot</surname>
                    <given-names>JD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gavin</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rudensky</surname>
                    <given-names>AY</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Foxp3 programs the development and function of CD4+CD25+ regulatory T cells.</article-title>
                <source>Nat Immunol</source>
                <volume>4</volume>
                <fpage>330</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">12612578</pub-id>
              </element-citation>
            </ref>
            <ref id="ipex.REF.gajiwala.2000.110">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gajiwala</surname>
                    <given-names>KS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Burley</surname>
                    <given-names>SK</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Winged helix proteins.</article-title>
                <source>Curr Opin Struct Biol</source>
                <volume>10</volume>
                <fpage>110</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">10679470</pub-id>
              </element-citation>
            </ref>
            <ref id="ipex.REF.gambineri.2008.1105">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gambineri</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Perroni</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Passerini</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bianchi</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Doglioni</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meschi</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bonfanti</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sznajer</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tommasini</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lawitschka</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Junker</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dunstheimer</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heidemann</surname>
                    <given-names>PH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cazzola</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cipolli</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Friedrich</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Janic</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Azzi</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Richmond</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vignola</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barabino</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chiumello</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Azzari</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roncarolo</surname>
                    <given-names>MG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bacchetta</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Clinical and molecular profile of a new series of patients with immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome: Inconsistent correlation between forkhead box protein 3 expression and disease severity.</article-title>
                <source>J Allergy Clin Immunol</source>
                <volume>122</volume>
                <fpage>1105</fpage>
                <lpage>12.e1</lpage>
                <pub-id pub-id-type="pmid">18951619</pub-id>
              </element-citation>
            </ref>
            <ref id="ipex.REF.gambineri.2003.430">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gambineri</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Torgerson</surname>
                    <given-names>TR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ochs</surname>
                    <given-names>HD</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Immune dysregulation, polyendocrinopathy, enteropathy, and X-linked inheritance (IPEX), a syndrome of systemic autoimmunity caused by mutations of FOXP3, a critical regulator of T-cell homeostasis.</article-title>
                <source>Curr Opin Rheumatol</source>
                <volume>15</volume>
                <fpage>430</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">12819471</pub-id>
              </element-citation>
            </ref>
            <ref id="ipex.REF.gavin.2006.6659">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gavin</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Torgerson</surname>
                    <given-names>TR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Houston</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>DeRoos</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ho</surname>
                    <given-names>WY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stray-Pedersen</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ocheltree</surname>
                    <given-names>EL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Greenberg</surname>
                    <given-names>PD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ochs</surname>
                    <given-names>HD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rudensky</surname>
                    <given-names>AY</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development.</article-title>
                <source>Proc Natl Acad Sci U S A</source>
                <volume>103</volume>
                <fpage>6659</fpage>
                <lpage>64</lpage>
                <pub-id pub-id-type="pmid">16617117</pub-id>
              </element-citation>
            </ref>
            <ref id="ipex.REF.glocker.2009.2033">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Glocker</surname>
                    <given-names>EO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kotlarz</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boztug</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gertz</surname>
                    <given-names>EM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sch&#x000e4;ffer</surname>
                    <given-names>AA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Noyan</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Perro</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Diestelhorst</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Allroth</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Murugan</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>H&#x000e4;tscher</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pfeifer</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sykora</surname>
                    <given-names>KW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sauer</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kreipe</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lacher</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nustede</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Woellner</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baumann</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salzer</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Koletzko</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shah</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Segal</surname>
                    <given-names>AW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sauerbrey</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Buderus</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Snapper</surname>
                    <given-names>SB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grimbacher</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Klein</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Inflammatory bowel disease and mutations affecting the interleukin-10 receptor.</article-title>
                <source>N Engl J Med</source>
                <volume>361</volume>
                <fpage>2033</fpage>
                <lpage>45</lpage>
                <pub-id pub-id-type="pmid">19890111</pub-id>
              </element-citation>
            </ref>
            <ref id="ipex.REF.hori.2003.1057">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hori</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nomura</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sakaguchi</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Control of regulatory T cell development by the transcription factor Foxp3.</article-title>
                <source>Science</source>
                <volume>299</volume>
                <fpage>1057</fpage>
                <lpage>61</lpage>
                <pub-id pub-id-type="pmid">12522256</pub-id>
              </element-citation>
            </ref>
            <ref id="ipex.REF.khattri.2003.337">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Khattri</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cox</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yasayko</surname>
                    <given-names>SA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ramsdell</surname>
                    <given-names>F</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>An essential role for Scurfin in CD4+CD25+ T regulatory cells.</article-title>
                <source>Nat Immunol</source>
                <volume>4</volume>
                <fpage>337</fpage>
                <lpage>42</lpage>
                <pub-id pub-id-type="pmid">12612581</pub-id>
              </element-citation>
            </ref>
            <ref id="ipex.REF.kobayashi.2001.874">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kobayashi</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shiari</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yamada</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kawamura</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Okano</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yara</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Iguchi</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ishikawa</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ariga</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sakiyama</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ochs</surname>
                    <given-names>HD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kobayashi</surname>
                    <given-names>K</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Novel mutations of FOXP3 in two Japanese patients with immune dysregulation, polyendocrinopathy, enteropathy, X linked syndrome (IPEX).</article-title>
                <source>J Med Genet</source>
                <volume>38</volume>
                <fpage>874</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">11768393</pub-id>
              </element-citation>
            </ref>
            <ref id="ipex.REF.kofoed.2003.1139">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kofoed</surname>
                    <given-names>EM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hwa</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Little</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Woods</surname>
                    <given-names>KA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Buckway</surname>
                    <given-names>CK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tsubaki</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pratt</surname>
                    <given-names>KL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bezrodnik</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jasper</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tepper</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heinrich</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rosenfeld</surname>
                    <given-names>RG</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Growth hormone insensitivity associated with a STAT5b mutation.</article-title>
                <source>N Engl J Med</source>
                <volume>349</volume>
                <fpage>1139</fpage>
                <lpage>47</lpage>
                <pub-id pub-id-type="pmid">13679528</pub-id>
              </element-citation>
            </ref>
            <ref id="ipex.REF.levylahad.2001.577">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Levy-Lahad</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wildin</surname>
                    <given-names>RS</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Neonatal diabetes mellitus, enteropathy, thrombocytopenia, and endocrinopathy: Further evidence for an X-linked lethal syndrome.</article-title>
                <source>J Pediatr</source>
                <volume>138</volume>
                <fpage>577</fpage>
                <lpage>80</lpage>
                <pub-id pub-id-type="pmid">11295725</pub-id>
              </element-citation>
            </ref>
            <ref id="ipex.REF.lopes.2006.3133">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lopes</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Torgerson</surname>
                    <given-names>TR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schubert</surname>
                    <given-names>LA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Anover</surname>
                    <given-names>SD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ocheltree</surname>
                    <given-names>EL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ochs</surname>
                    <given-names>HD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ziegler</surname>
                    <given-names>SF</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Analysis of FOXP3 reveals multiple domains required for its function as a transcriptional repressor.</article-title>
                <source>J Immunol</source>
                <volume>177</volume>
                <fpage>3133</fpage>
                <lpage>42</lpage>
                <pub-id pub-id-type="pmid">16920951</pub-id>
              </element-citation>
            </ref>
            <ref id="ipex.REF.lucas.2007.55">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lucas</surname>
                    <given-names>KG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ungar</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Comito</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bayerl</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Groh</surname>
                    <given-names>B</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Submyeloablative cord blood transplantation corrects clinical defects seen in IPEX syndrome.</article-title>
                <source>Bone Marrow Transplant</source>
                <volume>39</volume>
                <fpage>55</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">17115064</pub-id>
              </element-citation>
            </ref>
            <ref id="ipex.REF.mcginness.2006.143">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>McGinness</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bivens</surname>
                    <given-names>MM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Greer</surname>
                    <given-names>KE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Patterson</surname>
                    <given-names>JW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Saulsbury</surname>
                    <given-names>FT</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) associated with pemphigoid nodularis: a case report and review of the literature.</article-title>
                <source>J Am Acad Dermatol</source>
                <volume>55</volume>
                <fpage>143</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">16781310</pub-id>
              </element-citation>
            </ref>
            <ref id="ipex.REF.mcmurchy.2010.1242">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>McMurchy</surname>
                    <given-names>AN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gillies</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Allan</surname>
                    <given-names>SE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Passerini</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gambineri</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roncarolo</surname>
                    <given-names>MG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bacchetta</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Levings</surname>
                    <given-names>MK</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Point mutants of forkhead box P3 that cause immune dysregulation, polyendocrinopathy, enteropathy X-linked have diverse abilities to reprogram T cells into regulatory T cells.</article-title>
                <source>J Allergy Clin Immunol</source>
                <volume>126</volume>
                <fpage>1242</fpage>
                <lpage>51</lpage>
                <pub-id pub-id-type="pmid">21036387</pub-id>
              </element-citation>
            </ref>
            <ref id="ipex.REF.nieves.2004.466">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Nieves</surname>
                    <given-names>DS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Phipps</surname>
                    <given-names>RP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pollock</surname>
                    <given-names>SJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ochs</surname>
                    <given-names>HD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhu</surname>
                    <given-names>Q</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scott</surname>
                    <given-names>GA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ryan</surname>
                    <given-names>CK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kobayashi</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rossi</surname>
                    <given-names>TM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goldsmith</surname>
                    <given-names>LA</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Dermatologic and immunologic findings in the immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome.</article-title>
                <source>Arch Dermatol</source>
                <volume>140</volume>
                <fpage>466</fpage>
                <lpage>72</lpage>
                <pub-id pub-id-type="pmid">15096376</pub-id>
              </element-citation>
            </ref>
            <ref id="ipex.REF.ochs.2005.156">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ochs</surname>
                    <given-names>HD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ziegler</surname>
                    <given-names>SF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Torgerson</surname>
                    <given-names>TR</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>FOXP3 acts as a rheostat of the immune response.</article-title>
                <source>Immunol Rev</source>
                <volume>203</volume>
                <fpage>156</fpage>
                <lpage>64</lpage>
                <pub-id pub-id-type="pmid">15661028</pub-id>
              </element-citation>
            </ref>
            <ref id="ipex.REF.owen.2003.6034">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Owen</surname>
                    <given-names>CJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jennings</surname>
                    <given-names>CE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Imrie</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lachaux</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bridges</surname>
                    <given-names>NA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cheetham</surname>
                    <given-names>TD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pearce</surname>
                    <given-names>SH</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Mutational analysis of the FOXP3 gene and evidence for genetic heterogeneity in the immunodysregulation, polyendocrinopathy, enteropathy syndrome.</article-title>
                <source>J Clin Endocrinol Metab</source>
                <volume>88</volume>
                <fpage>6034</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">14671208</pub-id>
              </element-citation>
            </ref>
            <ref id="ipex.REF.powell.1982.731">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Powell</surname>
                    <given-names>BR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Buist</surname>
                    <given-names>NR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stenzel</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <year>1982</year>
                <article-title>An X-linked syndrome of diarrhea, polyendocrinopathy, and fatal infection in infancy.</article-title>
                <source>J Pediatr</source>
                <volume>100</volume>
                <fpage>731</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">7040622</pub-id>
              </element-citation>
            </ref>
            <ref id="ipex.REF.rao.2007.383">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Rao</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kamani</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Filipovich</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Davies</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dalal</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shenoy</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Successful bone marrow transplantation for IPEX syndrome after reduced-intensity conditioning.</article-title>
                <source>Blood</source>
                <volume>109</volume>
                <fpage>383</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">16990602</pub-id>
              </element-citation>
            </ref>
            <ref id="ipex.REF.roifman.2000.6">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Roifman</surname>
                    <given-names>CM</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Human IL-2 receptor alpha chain deficiency.</article-title>
                <source>Pediatr Res</source>
                <volume>48</volume>
                <fpage>6</fpage>
                <lpage>11</lpage>
                <pub-id pub-id-type="pmid">10879793</pub-id>
              </element-citation>
            </ref>
            <ref id="ipex.REF.ruemmele.2004.587">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ruemmele</surname>
                    <given-names>FM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brousse</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goulet</surname>
                    <given-names>O</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Autoimmune enteropathy: molecular concepts.</article-title>
                <source>Curr Opin Gastroenterol</source>
                <volume>20</volume>
                <fpage>587</fpage>
                <lpage>91</lpage>
                <pub-id pub-id-type="pmid">15703687</pub-id>
              </element-citation>
            </ref>
            <ref id="ipex.REF.sakaguchi.2003.1310">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sakaguchi</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>The origin of FOXP3-expressing CD4+ regulatory T cells: thymus or periphery.</article-title>
                <source>J Clin Invest</source>
                <volume>112</volume>
                <fpage>1310</fpage>
                <lpage>2</lpage>
                <pub-id pub-id-type="pmid">14597756</pub-id>
              </element-citation>
            </ref>
            <ref id="ipex.REF.sherman.2004.16">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sherman</surname>
                    <given-names>PM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mitchell</surname>
                    <given-names>DJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cutz</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Neonatal enteropathies: defining the causes of protracted diarrhea of infancy.</article-title>
                <source>J Pediatr Gastroenterol Nutr</source>
                <volume>38</volume>
                <fpage>16</fpage>
                <lpage>26</lpage>
                <pub-id pub-id-type="pmid">14676590</pub-id>
              </element-citation>
            </ref>
            <ref id="ipex.REF.strauss.2007.320">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Strauss</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Whiteside</surname>
                    <given-names>TL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Knights</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bergmann</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Knuth</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zippelius</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Selective survival of naturally occurring human CD4+CD25+Foxp3+ regulatory T cells cultured with rapamycin.</article-title>
                <source>J Immunol</source>
                <volume>178</volume>
                <fpage>320</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">17182569</pub-id>
              </element-citation>
            </ref>
            <ref id="ipex.REF.taddio.2007.1195">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Taddio</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Faleschini</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Valencic</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Granzotto</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tommasini</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lepore</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Andolina</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barbi</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ventura</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Medium-term survival without haematopoietic stem cell transplantation in a case of IPEX: insights into nutritional and immunosuppressive therapy.</article-title>
                <source>Eur J Pediatr</source>
                <volume>166</volume>
                <fpage>1195</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">17205241</pub-id>
              </element-citation>
            </ref>
            <ref id="ipex.REF.tommasini.2002.127">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tommasini</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ferrari</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moratto</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Badolato</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boniotto</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pirulli</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Notarangelo</surname>
                    <given-names>LD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Andolina</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>X-chromosome inactivation analysis in a female carrier of FOXP3 mutation.</article-title>
                <source>Clin Exp Immunol</source>
                <volume>130</volume>
                <fpage>127</fpage>
                <lpage>30</lpage>
                <pub-id pub-id-type="pmid">12296863</pub-id>
              </element-citation>
            </ref>
            <ref id="ipex.REF.torgerson.2007.1705">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Torgerson</surname>
                    <given-names>TR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Linane</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moes</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Anover</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mateo</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rieux-Laucat</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hermine</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vijay</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gambineri</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cerf-Bensussan</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fischer</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ochs</surname>
                    <given-names>HD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goulet</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ruemmele</surname>
                    <given-names>FM</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Severe food allergy as a variant of IPEX syndrome caused by a deletion in a noncoding region of the FOXP3 gene.</article-title>
                <source>Gastroenterology</source>
                <volume>132</volume>
                <fpage>1705</fpage>
                <lpage>17</lpage>
                <pub-id pub-id-type="pmid">17484868</pub-id>
              </element-citation>
            </ref>
            <ref id="ipex.REF.wildin.2002.537">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wildin</surname>
                    <given-names>RS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smyk-Pearson</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Filipovich</surname>
                    <given-names>AH</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Clinical and molecular features of the immunodysregulation, polyendocrinopathy, enteropathy, X linked (IPEX) syndrome.</article-title>
                <source>J Med Genet</source>
                <volume>39</volume>
                <fpage>537</fpage>
                <lpage>45</lpage>
                <pub-id pub-id-type="pmid">12161590</pub-id>
              </element-citation>
            </ref>
            <ref id="ipex.REF.yong.2008.581">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Yong</surname>
                    <given-names>PL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Russo</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sullivan</surname>
                    <given-names>KE</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Use of sirolimus in IPEX and IPEX-like children.</article-title>
                <source>J Clin Immunol</source>
                <volume>28</volume>
                <fpage>581</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">18481161</pub-id>
              </element-citation>
            </ref>
            <ref id="ipex.REF.zhou.2008.236">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Zhou</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lopes</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chong</surname>
                    <given-names>MM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ivanov</surname>
                    <given-names>II</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Min</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Victora</surname>
                    <given-names>GD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shen</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Du</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rubstov</surname>
                    <given-names>YP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rudensky</surname>
                    <given-names>AY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ziegler</surname>
                    <given-names>SF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Littman</surname>
                    <given-names>DR</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>TGF&#x003b2;-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing ROR&#x003b3;t function.</article-title>
                <source>Nature</source>
                <volume>453</volume>
                <fpage>236</fpage>
                <lpage>40</lpage>
                <pub-id pub-id-type="pmid">18368049</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="ipex.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="ipex.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>27 January 2011 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>12 December 2007 (me) Comprehensive update posted to live Web site</p>
            </list-item>
            <list-item>
              <p>27 April 2006 (cd) Revision: FOXP3 testing available clinically</p>
            </list-item>
            <list-item>
              <p>19 October 2004 (me) Review posted to live Web site</p>
            </list-item>
            <list-item>
              <p>11 February 2004 (mh) Original submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
